Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/1616
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDe Souza, Lauraen_US
dc.contributor.authorPrunster, J.en_US
dc.contributor.authorChan, D.en_US
dc.contributor.authorChakera, A.en_US
dc.contributor.authorLim, W. H.en_US
dc.date.accessioned2021-12-21T04:24:47Z-
dc.date.available2021-12-21T04:24:47Z-
dc.date.issued2021-
dc.identifier.citationDe Souza L, Prunster J, Chan D, Chakera A, Lim WH. Recurrent glomerulonephritis after kidney transplantation: a practical approach. Curr Opin Organ Transplant. 2021 Aug 1;26(4):360-380. doi: 10.1097/MOT.0000000000000887. PMID: 34039882.en_US
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/1616-
dc.descriptionCairns & Hinterland Hospital and Health Service (CHHHS) affiliated authors: Laura De Souza, Janelle Prunster.en_US
dc.description.abstractThis review will provide a practical approach in the assessment of kidney failure patients with primary glomerulonephritides (GN) being considered for kidney transplantation, focusing on high-risk subtypes of immunoglobulin A nephropathy, focal segmental glomerulosclerosis, idiopathic membranous glomerulonephritis and membranoproliferative glomerulonephritis. Recurrent glomerulonephritis remains one of the most common causes of allograft loss in kidney transplant recipients. Although the epidemiology and clinical outcomes of glomerulonephritis recurrence occurring after kidney transplantation are relatively well-described, the natural course and optimal treatment strategies of recurrent disease in kidney allografts remain poorly defined. With a greater understanding of the pathophysiology and treatment responses of patients with glomerulonephritis affecting the native kidneys, these discoveries have laid the framework for the potential to improve the management of patients with high-risk glomerulonephritis subtypes being considered for kidney transplantation. Advances in the understanding of the underlying immunopathogenesis of primary GN has the potential to offer novel therapeutic options for kidney patients who develop recurrent disease after kidney transplantation. To test the efficacy of novel treatment options in adequately powered clinical trials requires a more detailed understanding of the clinical and histological characteristics of kidney transplant recipients with recurrent glomerulonephritis.en_US
dc.language.isoenen_US
dc.publisherWolters Kluweren_US
dc.relation.ispartofCurrent opinion in organ transplantationen_US
dc.subjectadverse eventen_US
dc.subjectfocal glomerulosclerosisen_US
dc.subjectglomerulonephritisen_US
dc.subjecthuman immunoglobulin A nephropathyen_US
dc.subjectkidney transplantationen_US
dc.subjectmembranoproliferative glomerulonephritisen_US
dc.subjectmembranous glomerulonephritisen_US
dc.subjectrecurrent diseaseen_US
dc.titleRecurrent glomerulonephritis after kidney transplantation: a practical approachen_US
dc.typeArticleen_US
dc.identifier.doi10.1097/MOT.0000000000000887-
item.languageiso639-1en-
item.openairetypeArticle-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Appears in Sites:Cairns & Hinterland HHS Publications
Show simple item record

Page view(s)

66
checked on Jan 8, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.